ACET
HEALTHCAREAdicet Bio Inc
$8.55+0.04 (+0.47%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving ACET Today?
No stock-specific AI insight has been generated for ACET yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.01$17.44
$8.55
Fundamentals
Market Cap$80M
P/E Ratio—
EPS$-16.95
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume113K
Avg Volume (10D)—
Shares Outstanding9.3M
ACET News
20 articles- Adicet Bio (ACET) Upgraded to Buy: Here's WhyYahoo Finance·Mar 24, 2026
- Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company ProgressYahoo Finance·Mar 12, 2026
- Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Jan 30, 2026
- Adicet Bio Provides Corporate Update and Highlights Expected 2026 MilestonesYahoo Finance·Jan 7, 2026
- Adicet Bio Announces Reverse Stock SplitYahoo Finance·Dec 26, 2025
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Nov 28, 2025
- MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceYahoo Finance·Nov 12, 2025
- Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Nov 5, 2025
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Oct 31, 2025
- Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Oct 28, 2025
- Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)Yahoo Finance·Oct 16, 2025
- Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?Yahoo Finance·Oct 7, 2025
- Adicet Bio, Inc. Announces $80 Million Registered Direct OfferingYahoo Finance·Oct 7, 2025
- Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)Yahoo Finance·Oct 7, 2025
- Adicet Bio (ACET) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Sep 30, 2025
- Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- MaxCyte (MXCT) Signed a Strategic Platform License with Adicet BioYahoo Finance·Aug 11, 2025
- Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Aug 7, 2025
- MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 GuidanceYahoo Finance·Aug 6, 2025
- Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth ConferenceYahoo Finance·Aug 5, 2025
All 20 articles loaded
Price Data
Open$8.51
Previous Close$8.51
Day High$8.77
Day Low$8.37
52 Week High$17.44
52 Week Low$6.01
52-Week Range
$6.01$17.44
$8.55
Fundamentals
Market Cap$80M
P/E Ratio—
EPS$-16.95
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume113K
Avg Volume (10D)—
Shares Outstanding9.3M
About Adicet Bio Inc
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—